About us

Vision & Mission

SideROS aims to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.

SideROS bridges innovative research on iron-targeting chemical compounds and drug candidate discoveries to target persister cancer cells, refractory to conventional treatments and associated to metastasis and relapse. The role of iron is ubiquitous whatever the origin of cancer cells, suggesting that our small molecules can target various types of cancer.

History

SideROS was founded in January 2019 based on the research from Dr Raphaël Rodriguez, a world renowned scientist devoted to understand persister cancer cells biology, the role of iron homeostasis in those cells and know how to target them and Robin Rivaton, as business advisor. The company is incubated at ICM since September 2019.

Values

SideROS aims to eradicate cancer cells responsible of relapses and metastates and to improve the conditions of patients affected by life-threatening diseases lacking of effective treatment.

Dr Raphaël Rodriguez, Research Director
Founder

at Curie Institute, performed his PhD studies under the supervision of Prof Sir Jack E. Baldwin and Prof Maurice Santelli at the University of Oxford and in Marseille, where he completed the synthesis of structurally complex natural products by means of pericyclic processes. He joined The University of Cambridge in November 2005 as a postdoctoral fellow, together with Prof. Steve Jackson (Gurdon Institute, UK), they firmly established a link between G-quadruplex DNA structures and genomic instability. Raphaël joined the CNRS as a group leader in 2012 and was promoted Director of Research at Institut Curie in 2017. His recent achievements include the development of the anti-aging small molecule remodelin, the first chemical synthesis of the complex natural product marmycin and the iron metabolism targeting drug ironomycin. His group has recently elucidated the mechanism of action of salinomycin against persister cancer cells and identified a role of iron in the maintenance of these cells.

Awards 2019: Tetrahedron Young Investigator Award

2019: i-Lab Award for the company SideROS

2019: Grand Prix de l’Institut de France ‘Charles Defforey’

2019: SUNRISE Cancer Stem Cell Award

2019: Grand Prix du Collège de France (Lacassagne)

2017: Fellow of the Royal Society of Chemistry (FRSC)

Robin Rivaton
Founder

is a VC Investor in Smart City (IDInvest), author (8 books), former consultant (BCG, Paris Airports), independant board member (Sogeprom, Manuloc)

Management Team

Dr Lucie Mondoulet, CEO A new direction was taken after being awarded by i-lab grants in July 2019. Following promising preliminary in vitro and in vivo results from our proprietary and patented small molecules against persister cancer cells. Dr Lucie Mondoulet joined the company as CEO in July 2019. Lucie holds a PhD in biochemical engineering and HDR in immunology combined with a biotech expertise by spending more than 11 years at DBV Technologies acting from discovery to clinical phase, where she has set-up & Lead Research and Innovation Department (8 patents/2 granted).

Nathalie Donne joins the company as Business advisor in July 2019. She holds an Msc in Biology & Msc Masternova & an Executive MBA at INSEAD, with a biotech expertise after spending more than 15 years at DBV Technologies as VP Business Development and Alliance Management. In July 2018, she Co-founded of a consulting company dedicated to innovation

Dr. Laurent Martin, Pharmacist (Paris V) and holding an MBA joins the company as Development Advisor in September 2019. With a Pharma (3 years at Guerbet & 6 years at Orphan Europe) and biotech expertise (12 years at DBV Technologies), he is the right advisor for bringing SideROS to the right development path with his expertise in the elaboration and management of strategic development plan for new drugs (FDA/EMA)

contact@sideros.bio

Incubated at iPEP’s ICM in Pitié-Salpétrière Hospital

Fill out the form below and we will answer all of your queries